Mexico - Delayed Quote MXN

Amgen Inc. (AMGN.MX)

5,390.00

0.00

(0.00%)

At close: January 8 at 2:39:57 PM CST

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investor's Business Daily 3 days ago

AMGN

LLY

PFE
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.

Zacks 3 days ago

VKTX

AMGN
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

PR Newswire 4 days ago

AMGN
Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th of...

Simply Wall St. 6 days ago

AMGN
Prediction: These 3 Healthcare Stocks Will Soar in 2025

Here's why they chose Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Summit Therapeutics (NASDAQ: SMMT). David Jagielski (Amgen): Shares of Amgen started crashing in late November following the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide.

Motley Fool 8 days ago

LLY

SMMT

AMGN
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 9 days ago

AMGN
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The Dow Jones Industrial Average contains 30 handpicked companies that are, or at least once were, leaders in their respective industries. Right now the three highest yielding Dow stocks are Verizon Communications (NYSE: VZ), Chevron (NYSE: CVX), and Amgen (NASDAQ: AMGN). Verizon is one of the largest telecom companies in the United States.

Motley Fool 9 days ago

CVX

VZ

AMGN
The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.

TheStreet 11 days ago

^DJI

JNJ

BA
Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.

Zacks 12 days ago

AMGN
GLP-1 questions emerge for 2025

The 2025 outlook for GLP-1s isn't as bullish as it once was, but all hope is not lost.

Yahoo Finance 12 days ago

LLY

AMGN

NONOF
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.

Zacks 13 days ago

AMGN
Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower […]

Insider Monkey 13 days ago

AMGN
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 16 days ago

AMGN
3 Healthcare Stocks to Buy for a 2025 Rebound

The Health Care Select Sector SPDR exchange-traded fund has gained 1.2% in 2024, lagging the S&P 500’s 24% gain. Health insurers are generally best avoided now (United Health might be an exception), but there are other opportunities. Two companies with GLP-1 weight loss drugs that might be buying opportunities now are Amgen and Eli Lilly.

Barrons.com 17 days ago

LLY

AMGN
What's next for GLP-1 weight-loss drugs in 2025?

GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea treatments. Yahoo Finance Health Reporter Anjalee Khemlani dives into the details, analyzing the outlook for GLP-1 drugs as markets head into 2025. Also, catch Anjalee Khemlani highlight the three biggest catalysts for the healthcare industry expected in the new year. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Yahoo Finance Video 19 days ago

LLY

AMGN

NONOF
3 biggest catalysts expected for healthcare in 2025

After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drugs and proposed regulations on pharmacy benefit managers (PBMs) from the second Trump administration. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 19 days ago

NONOF

NVO

LLY
Here's Why Amgen (AMGN) Gained But Lagged the Market Today

The latest trading day saw Amgen (AMGN) settling at $264, representing a +0.24% change from its previous close.

Zacks 20 days ago

AMGN

^GSPC
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Zacks 20 days ago

AMGN
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?

Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 20 days ago

TWST

AMGN
Lilly's Zepbound Receives FDA Approval for Sleep Apnea

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Zacks 20 days ago

LLY

NVO

AMGN

Performance Overview

Return	AMGN.MX	S&P 500
YTD	+1.13%	-1.35%
1-Year	+10.72%	+22.51%
3-Year	+16.82%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMGN.MX)

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year

Prediction: These 3 Healthcare Stocks Will Soar in 2025

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The 5 worst-performing stocks on the Dow Jones Industrial Average in 2024

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

GLP-1 questions emerge for 2025

Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Is Amgen Inc. (AMGN) the Best Pharma Dividend Stock to Buy In 2024?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

3 Healthcare Stocks to Buy for a 2025 Rebound

What's next for GLP-1 weight-loss drugs in 2025?

3 biggest catalysts expected for healthcare in 2025

Here's Why Amgen (AMGN) Gained But Lagged the Market Today

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?

Lilly's Zepbound Receives FDA Approval for Sleep Apnea

Performance Overview